Biostax Corp.
Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset,… Read more
Biostax Corp. (BTAX) - Total Assets
Latest total assets as of March 2025: $5.50K USD
Based on the latest financial reports, Biostax Corp. (BTAX) holds total assets worth $5.50K USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biostax Corp. - Total Assets Trend (2019–2023)
This chart illustrates how Biostax Corp.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biostax Corp. - Asset Composition Analysis
Current Asset Composition (December 2023)
Biostax Corp.'s total assets of $5.50K consist of 84.4% current assets and 15.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $708.19K | 2007.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how Biostax Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biostax Corp.'s current assets represent 84.4% of total assets in 2023, a decrease from 84.7% in 2019.
- Cash Position: Cash and equivalents constituted 84.4% of total assets in 2023, down from 84.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2007.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 2007.1% of total assets.
Biostax Corp. Competitors by Total Assets
Key competitors of Biostax Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Biostax Corp. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Biostax Corp. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Biostax Corp. is currently not profitable relative to its asset base.
Biostax Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.00 | 0.07 |
| Quick Ratio | 0.00 | 0.00 | 0.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.33 Million | $ -4.21 Million | $ -2.60 Million |
Biostax Corp. - Advanced Valuation Insights
This section examines the relationship between Biostax Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | -96.3% |
| Total Assets | $35.28K |
| Market Capitalization | $8.37K USD |
Valuation Analysis
Below Book Valuation: The market values Biostax Corp.'s assets below their book value (0.24 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biostax Corp.'s assets decreased by 96.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biostax Corp. (2019–2023)
The table below shows the annual total assets of Biostax Corp. from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $35.28K | -96.34% |
| 2022-12-31 | $963.72K | -69.30% |
| 2021-12-31 | $3.14 Million | +30761.12% |
| 2020-12-31 | $10.17K | +74.88% |
| 2019-12-31 | $5.82K | -- |